1. The Multifaceted Nature of Psoriasis Addressing Patients' Needs

2. Epidemiology of Psoriasis

3. Psoriasis: A Systemic Disease

4. Prevalence of Different Psoriasis Manifestations

5. The Dermatologic Intimacy Scale: Quantitatively Measuring the Impact of Skin Disease on Intimacy

6. Delayed Diagnosis of PsA Is Associated With Worse Long-Term Outcomes

7. Screening Tools: Derm Perspective

8. Poor Communication and Low HCP Awareness

9. Many Patients With Severe Psoriasis Report Inappropriate Treatment

10. Therapies for Moderate-To-Severe Psoriasis

11. TNF Inhibitors in PsA: ACR20 and ACR50 Responses

12. Non-TNF Biologics in PsA: ACR20 Response

13. Non-TNF Biologics in PsA: ACR50 Response

14. Nail Psoriasis: Adalimumab RCT and Ixekizumab Sub-Analysis

15. Scalp Psoriasis: Secukinumab RCT Patients With Moderate-To-Severe Scalp PsO Without Requirement of BSA >10% (N = 102)

16. Genital Psoriasis: Ixekizumab RCT Patients With Moderate-To-Severe GenPs With BSA ≥1% (N = 149)

17. Palmoplantar Psoriasis: RCT Infliximab and Secukinumab

18. Treatment Targets

19. Choosing a Target: VLDA/MDA

20. Does MDA Matter?

21. Importance of the Physician-Patient Relationship and the Role of a Multidisciplinary Team

22. Conclusions

23. Abbreviations

24. Abbreviations (cont)

25. Abbreviations (cont)